Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Sponsor: Dendreon
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
Margaret Warner-Lubin · 2064588358 · ProvONE@dendreon.com
Always discuss trial participation with your own doctor first.
| Arizona Urology Specialists | Tuscon, Arizona, United States | Recruiting |
| City of Hope - National Medical Center | Duarte, California, United States | Recruiting |
| Urology Associates of Central California Medical Group | Fresno, California, United States | Recruiting |
| Unio Health Partners - Genesis Research, LLC | San Diego, California, United States | Recruiting |
| Colorado Urology | Lakewood, Colorado, United States | Recruiting |
| Advanced Urology Institute | Daytona Beach, Florida, United States | Recruiting |
| Advanced Urology Institute | Largo, Florida, United States | Recruiting |
| Advanced Urology Institute | Ocala, Florida, United States | Recruiting |
| Florida Urology Partners | Riverview, Florida, United States | Recruiting |
| Associated Urological Specialists | Chicago Ridge, Illinois, United States | Active Not Recruiting |
| UroPartners | Glenview, Illinois, United States | Recruiting |
| Advanced Urology Associates | New Lenox, Illinois, United States | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06134232